[Renal cell carcinoma and antiangiogenic agents: ongoing controversies are seeking answers for improvement of therapeutic management].

Abstract

The recent development of agents targeting VHL-related growth factors as therapy for metastatic renal cell carcinoma has generated a revolution in the management of these patients, with a clear improvement of survival. However, there are still many questions related to these antiangiogenic agents and upcoming studies are strongly warranted to provide answers. The controversy is ongoing regarding several specific questions as the use of antiangiogenic treatments remains a moot point in certain cases. Notably, the role for radical nephrectomy in metastatic cases, the interest of adjuvant treatment in high-risk recurrence cases, the place for neoadjuvant treatment in locally advanced renal cell carcinoma, the choice of the best agent at first-line treatment, the various therapeutic options and their consequences on the quality of life and the potential contribution of dynamic imaging to assess antiangiogenic treatment's efficiency.

• Authors: F Audenet, M Rouprêt, A Méjean
• Journal: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie (Prog Urol) Vol. 19 Issue 9 Pg. 596-605 (Oct 2009) ISSN: 1166-7087 [Print] France
• Vernacular Title: Cancer du rein et thérapies ciblées : controverses sur les prises en charge thérapeutiques.
• PMID: 19800548 (Publication Type: English Abstract, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal

Topics

• Angiogenesis Inhibitors (therapeutic use)
• Antibodies, Monoclonal (therapeutic use)
• Carcinoma, Renal Cell (drug therapy, epidemiology)
• Drug Therapy, Combination
• Humans
• Kidney Neoplasms (drug therapy, epidemiology)